Ubs Group Ag Phio Pharmaceuticals Corp. Call Options Transaction History

Ubs Group Ag

  • $397 Billion
  • Q1 2024

Call Options

0 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
No transaction found.

Others Institutions Holding PHIO

# of Institutions
1
Shares Held
0
Call Options Held
0
Put Options Held
0
View Full List

About Phio Pharmaceuticals Corp.

PHIO Quotes by TradingView
  • Ticker PHIO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 13,658,700
  • Market Cap $7.92M
  • Description
  • Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint...
More about PHIO
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email